title: Impact of concomitant thyroid pathology on preoperative workup for primary hyperparathyroidism.
abstract: BACKGROUND
  The former standard surgical treatment in patients with primary hyperparathyroidism (pHPT) has been bilateral cervical exploration. New localization techniques and the possibility of intraoperative measurement of intact parathormone (iPTH) permit a focused, minimally invasive parathyroidectomy (MIP). The introduction of MIP without complete neck exploration leads to the potential risk of missing thyroid pathology. The aim of the present study is to evaluate the value of MIP in respect to coexisting thyroid findings and their impact on preoperative workup for primary hyperparathyroidism.
  
  
  METHODS
  This is a prospective study including 30 consecutive patients with pHPT (median age 65 years; 17 females, 13 males). In all patients preoperative localization was performed by ultrasonography and 99m Tc-MIBI scintigraphy- Intraoperative iPTH monitoring was routinely done.
  
  
  RESULTS
  Ten patients (33%) had a concurrent thyroid finding requiring additional thyroid surgery, and two patients (7%) with negative localization results underwent bilateral neck exploration. Therefore, MIP was attempted in 18 (60%) patients. The conversion rate to a four gland exploration was 6% (1/18). The sensitivities of 99m Tc-MIBI scanning and ultrasonography were 83.3% and 76.6%, respectively. The respective accuracy rates were 83.3% and 76.6%. Of note, the combination of the two modalities did not improve the sensitivity and accuracy in our patient population. During a median follow-up of 40 months, none of the patients developed persistent or recurrent hypocalcaemia, resulting in a 100% cure rate.
  
  
  CONCLUSIONS
  Coexisting thyroid pathology is relatively frequent in patients with pHPT in our region. Among patients having pHPT without any thyroid pathology, the adenoma localization is correct with either ultrasonography or 99m Tc-MIBI scintigraphy in the majority of cases. MIP with iPTH monitoring are highly successful in this group of patients and this operative technique should be the method of choice.
authors.affiliation: Allgemeinchirurgische Klinik, Universitätsspital Basel, Spitalstr. 21, CH-4031 Basel, Switzerland. oheizmann@uhbs.ch
authors.forename: Oleg
authors.initials: O
authors.lastname: Heizmann
authors.forename: C T
authors.initials: CT
authors.lastname: Viehl
authors.forename: R
authors.initials: R
authors.lastname: Schmid
authors.forename: J
authors.initials: J
authors.lastname: Müller-Brand
authors.forename: B
authors.initials: B
authors.lastname: Müller
authors.forename: D
authors.initials: D
authors.lastname: Oertli
mesh_terms: D000236:Adenoma / Q000150:complications* / Q000000981:diagnostic imaging; D000328:Adult; D000368:Aged; D005260:Female; D006801:Humans; D006961:Hyperparathyroidism / Q000150:complications* / Q000175:diagnosis / Q000601:surgery; D008297:Male; D008875:Middle Aged; D019060:Minimally Invasive Surgical Procedures / Q000379:methods; D016343:Monitoring, Intraoperative / Q000379:methods; D010281:Parathyroid Hormone / Q000097:blood; D016105:Parathyroidectomy; D011300:Preoperative Care; D011446:Prospective Studies; D011877:Radionuclide Imaging; D015203:Reproducibility of Results; D017256:Technetium Tc 99m Sestamibi / Q000008:administration & dosage; D013964:Thyroid Neoplasms / Q000150:complications* / Q000000981:diagnostic imaging; D014463:Ultrasonography
chemical_list: D010281:Parathyroid Hormone; D017256:Technetium Tc 99m Sestamibi